Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort.
Savage MJ, Holder DJ, Wu G, Kaplow J, Siuciak JA, Potter WZ; Foundation for National Institutes of Health (FNIH) Biomarkers Consortium CSF Proteomics Project Team for Alzheimer's Disease Neuroimaging Initiative. Savage MJ, et al. Among authors: holder dj. J Alzheimers Dis. 2015;46(2):431-40. doi: 10.3233/JAD-142778. J Alzheimers Dis. 2015. PMID: 25790831 Free PMC article.
Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD. Seeburger JL, et al. Among authors: holder dj. J Alzheimers Dis. 2015;44(2):525-39. doi: 10.3233/JAD-141725. J Alzheimers Dis. 2015. PMID: 25391385
High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal Fluid.
Hendrickson RC, Lee AY, Song Q, Liaw A, Wiener M, Paweletz CP, Seeburger JL, Li J, Meng F, Deyanova EG, Mazur MT, Settlage RE, Zhao X, Southwick K, Du Y, Holder D, Sachs JR, Laterza OF, Dallob A, Chappell DL, Snyder K, Modur V, King E, Joachim C, Bondarenko AY, Shearman M, Soper KA, Smith AD, Potter WZ, Koblan KS, Sachs AB, Yates NA. Hendrickson RC, et al. PLoS One. 2015 Aug 13;10(8):e0135365. doi: 10.1371/journal.pone.0135365. eCollection 2015. PLoS One. 2015. PMID: 26270474 Free PMC article. Clinical Trial.
CNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition.
Dobrowolska JA, Michener MS, Wu G, Patterson BW, Chott R, Ovod V, Pyatkivskyy Y, Wildsmith KR, Kasten T, Mathers P, Dancho M, Lennox C, Smith BE, Gilberto D, McLoughlin D, Holder DJ, Stamford AW, Yarasheski KE, Kennedy ME, Savage MJ, Bateman RJ. Dobrowolska JA, et al. Among authors: holder dj. J Neurosci. 2014 Jun 11;34(24):8336-46. doi: 10.1523/JNEUROSCI.0540-14.2014. J Neurosci. 2014. PMID: 24920637 Free PMC article.
A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging.
Mo Y, Stromswold J, Wilson K, Holder D, Sur C, Laterza O, Savage MJ, Struyk A, Scheltens P, Teunissen CE, Burke J, Macaulay SL, Bråthen G, Sando SB, White LR, Weiss C, Cowes A, Bush MM, DeSilva G, Darby DG, Rainey-Smith SR, Surls J, Sagini E, Tanen M, Altman A, Luthman J, Egan MF. Mo Y, et al. Alzheimers Dement (Amst). 2017 Mar 6;6:201-209. doi: 10.1016/j.dadm.2017.02.004. eCollection 2017. Alzheimers Dement (Amst). 2017. PMID: 28349119 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 32556126
77 results